Clinical Trial

Remimazolam for Cataract Surgery

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 19, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to assess any post operative cognitive changes following benzodiazepine administration during cataract surgery. The investigators will compare effects of Midazolam vs. Remimazolam on cognition at the time of discharge from the post operative care unit and the next day following surgery. Cognitive changes will be assessed by administration of Montreal Cognitive Assessment (MoCA). Participants will: 1. Complete MoCA testing prior to surgery 2. Randomize in either Midazolam or study drug Remimazolam 3. Complete MoCA testing after surgery at the time of discharge in the post anesthesia care unit and the next day of surgery at the time of post operative surgical visit. 4. Complete Patient Satisfaction Survey at the time of discharge from the Post Anesthesia Care Unit (PACU)
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-08-04; most recent amendment 2025-03-17.
Status change: Not Yet Recruiting → Recruiting 2025-03-17
Trial Details
NCT Number NCT05980117
Lead Sponsor University of California, Los Angeles
Conditions Cataract Surgery, Cognitive Impairment
Enrollment 120 participants
Start Date 2025-03-10
Primary Completion 2025-12 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-19